Disc Medicine’s updated DISC-0974 data ‘look good,’ says Cantor Fitzgerald

Cantor Fitzgerald notes that Disc Medicine (IRON) had several updates at ASH this weekend, with the biggest focus on updated Phase 1b data of DISC-0974 in myelofibrosis anemia, which the firm argues “look good no matter how you slice it.” It is “encouraging” to see that DISC-0974 has profound effects across all the major patient populations evaluated and that the results are durable, adds the analyst, who has an Overweight rating and $99 price target on Disc shares.